within Pharmacolibrary.Drugs.ATC.L;

model L01EX13
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.79,
    Cl             = 0.00031999999999999997,
    adminDuration  = 600,
    adminMass      = 120 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 1.09,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0004166666666666667,
    Tlag           = 1800,            
    Vdp             = 0.699,
    k12             = 223,
    k21             = 223
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L01EX13</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Gilteritinib is an oral, small molecule tyrosine kinase inhibitor that selectively inhibits FLT3 and AXL. It is used primarily in the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with FLT3 mutations. Gilteritinib is approved by regulatory authorities such as the FDA and EMA.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters from adult patients with relapsed/refractory AML, primarily under steady-state conditions at a standard therapeutic dose.</p><h4>References</h4><ol><li><p>Perl, AE, et al., &amp; Levis, M (2017). Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study. <i>The Lancet. Oncology</i> 18(8) 1061–1075. DOI:<a href=\"https://doi.org/10.1016/S1470-2045(17)30416-3\">10.1016/S1470-2045(17)30416-3</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/28645776/\">https://pubmed.ncbi.nlm.nih.gov/28645776</a></p></li><li><p>Tollkuci, E, et al., &amp; Myers, R (2021). Gilteritinib administration in a hemodialysis patient. <i>Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners</i> 27(5) 1255–1257. DOI:<a href=\"https://doi.org/10.1177/1078155220973259\">10.1177/1078155220973259</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33175659/\">https://pubmed.ncbi.nlm.nih.gov/33175659</a></p></li><li><p>Garrison, DA, et al., &amp; Baker, SD (2021). Development, validation, and application of an LC-MS/MS method for the determination of the AXL/FLT3 inhibitor gilteritinib in mouse plasma. <i>Journal of chromatography. B, Analytical technologies in the biomedical and life sciences</i> 1179 122882–None. DOI:<a href=\"https://doi.org/10.1016/j.jchromb.2021.122882\">10.1016/j.jchromb.2021.122882</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34365291/\">https://pubmed.ncbi.nlm.nih.gov/34365291</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L01EX13;
